Literature DB >> 23100729

Preparation of FMD type A87/IRN inactivated vaccine by gamma irradiation and the immune response on guinea pig.

Farahnaz Motamedi Sedeh1, Akbar Khorasani, Kamal Shafaee, Hadi Fatolahi, Kourosh Arbabi.   

Abstract

FMD is one of the most economically damaging diseases that affect livestock animals. In this study FMD Virus type A87/IRN was multiplied on BHK21 cells. The virus was titrated by TCID50 method, it was 10(7.5)/ml. The FMD virus samples were inactivated by gamma ray from 60Co source at -20°C. Safety test was done by IBRS2 monolayer cell culture method, also antigenicity of irradiated and un-irradiated virus samples were studied by Complement Fixation Test. The Dose/Survival curve for irradiated FMD Virus was drawn, the optimum dose range for inactivation of FMDV type A87/IRN and unaltered antigenicity was obtained 40-44 kGy. The inactivated virus samples by irradiation and ethyleneimine (EI) were formulated respectively as vaccine with Al(OH)3 gel and other substances. The vaccines were inoculated to Guinea pigs and the results of Serum Neutralization Test for the normal vaccine and radio-vaccine showed protective titer after 8 months. The potency test of the inactivated vaccines was done, PD50 Value of the vaccines were calculated 7.06 and 5.6 for inactivated vaccine by EI and gamma irradiation respectively.

Entities:  

Keywords:  Foot and Mouth Disease; Vaccine; Virus; gamma irradiation

Year:  2008        PMID: 23100729      PMCID: PMC3476770          DOI: 10.1007/s12088-008-0023-4

Source DB:  PubMed          Journal:  Indian J Microbiol        ISSN: 0046-8991            Impact factor:   2.461


  8 in total

1.  The action of ionizing radiation on viruses.

Authors:  E POLLARD
Journal:  Adv Virus Res       Date:  1954       Impact factor: 9.937

Review 2.  Developments in foot-and-mouth disease vaccines.

Authors:  S J Barteling; J Vreeswijk
Journal:  Vaccine       Date:  1991-02       Impact factor: 3.641

3.  Immune response to virus-infection-associated (VIA) antigen in cattle repeatedly vaccinated with foot-and-mouth disease virus inactivated by formalin or acetylethyleneimine.

Authors:  A A Pinto; A J Garland
Journal:  J Hyg (Lond)       Date:  1979-02

4.  Protective immune response of the capsid precursor polypeptide (P1) of foot and mouth disease virus type 'O' produced in Pichia pastoris.

Authors:  V Balamurugan; R Renji; S N Saha; G R Reddy; S Gopalakrishna; V V S Suryanarayana
Journal:  Virus Res       Date:  2003-04       Impact factor: 3.303

5.  Studies of the foot-and-mouth disease virus sub-types using antigens inactivated by gamma radiations.

Authors:  T Frescura; P Vivoli
Journal:  Zentralbl Veterinarmed B       Date:  1973-12

6.  Protective immunity against foot-and-mouth disease virus induced by a recombinant vaccinia virus.

Authors:  A Berinstein; C Tami; O Taboga; E Smitsaart; E Carrillo
Journal:  Vaccine       Date:  2000-04-28       Impact factor: 3.641

7.  Ultrastructural and replicative features of foot-and-mouth disease virus in persistently infected BHK-21 cells.

Authors:  A Donn; M Castagnaro; A I Donaldson
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

8.  Quantitative analysis of foot-and-mouth disease virus RNA loads in bovine tissues: implications for the site of viral persistence.

Authors:  Zhidong Zhang; Soren Alexandersen
Journal:  J Gen Virol       Date:  2004-09       Impact factor: 3.891

  8 in total
  2 in total

1.  Validation of γ-radiation and ultraviolet as a new inactivators for foot and mouth disease virus in comparison with the traditional methods.

Authors:  Safy El Din Mahdy; Amr Ismail Hassanin; Wael Mossad Gamal El-Din; Ehab El-Sayed Ibrahim; Hiam Mohamed Fakhry
Journal:  Vet World       Date:  2015-09-19

2.  Seroprevalence of some Infectious transboundry diseases in cattle imported from Sudan to Egypt.

Authors:  Sahar Hussein Abdalla Hekal; Magdy Hassanein Al-Gaabary; Magdy Mahmoud El-Sayed; Hassan Mohamed Sobhy; Adel Abdul Azim Fayed
Journal:  J Adv Vet Anim Res       Date:  2019-02-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.